Fourpath Capital Management
VRTX icon

Fourpath Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fourpath Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$600K Sell
1,147
-221
-16% -$113K 0.08% 147
2026
Q2 		$680K Sell
1,368
-319
-19% -$141K 0.09% 147
2026
Q1 		$753K Sell
1,687
-81
-5% -$37.8K 0.11% 124
2025
Q4 		$802K Buy
1,768
+109
+7% +$47K 0.11% 114
2025
Q3 		$650K Buy
1,659
+280
+20% +$117K 0.09% 131
2025
Q2 		$614K Sell
1,379
-188
-12% -$86.6K 0.1% 127
2025
Q1 		$760K Sell
1,567
-130
-8% -$60.6K 0.13% 102
2024
Q4 		$683K Sell
1,697
-2
-0.1% -$927 0.13% 113
2024
Q3 		$790K Buy
1,699
+30
+2% +$14.4K 0.15% 106
2024
Q2 		$782K Sell
1,669
-161
-9% -$69.9K 0.58% 37
2024
Q1 		$765K Sell
1,830
-75
-4% -$31.7K 0.53% 42
2023
Q4 		$775K Sell
1,905
-136
-7% -$50.2K 0.53% 40
2023
Q3 		$710K Sell
2,041
-56
-3% -$19.6K 0.53% 41
2023
Q2 		$738K Sell
2,097
-32
-2% -$10.8K 0.89% 36
2023
Q1 		$671K Sell
2,129
-27
-1% -$8.1K 0.47% 54
2022
Q4 		$623K Sell
2,156
-71
-3% -$21.6K 0.45% 57
2022
Q3 		$645K Sell
2,227
-596
-21% -$171K 0.44% 54
2022
Q2 		$795K Sell
2,823
-769
-21% -$206K 0.49% 48
2022
Q1 		$937K Sell
3,592
-354
-9% -$84K 0.37% 47
2021
Q4 		$867K Buy
+3,946
New +$767K 0.33% 55

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Fourpath Capital Management's VRTX Position: Q3 2026 in Review

Fourpath Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q3 2026, selling an estimated $113K and leaving 1,147 shares worth $600K. The position accounts for 0.08% of the portfolio, ranked #147.

Fourpath Capital Management first reported a position in VRTX in Q4 2021 and has held it in 20 quarters since. The position peaked at $937K in Q1 2022. 386 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Fourpath Capital Management held 1,147 shares of Vertex Pharmaceuticals worth $600K as of Q3 2026.
  • Fourpath Capital Management sold 221 Vertex Pharmaceuticals shares in Q3 2026, an estimated $113K.
  • Vertex Pharmaceuticals made up 0.08% of Fourpath Capital Management's portfolio in Q3 2026, its #147 holding.
  • Fourpath Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 20 quarters since.
  • Fourpath Capital Management's Vertex Pharmaceuticals position peaked at $937K in Q1 2022.
  • 386 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Fourpath Capital Management's 13F filing for Q3 2026, filed 19 Oct 2026.